We’re awaiting earnings from Pfizer this morning, which is simultaneously trying to acquire U.K. drugmaker AstraZeneca–in a deal that may cost it much more than the $106 billion it already offered. Orbitz is set to report earnings as well–after underperforming competitors Priceline and Tripadvisor, analysts are forecasting a loss. And Jim Cramer is charged up over one pick he’s saying could catch fire in emerging markets.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
